Medically appropriate and inappropriate opioid use is not always clear, FDA notes. CDP 860 are expected to be available by the end of the year. Zymogenetics will use initial public offering funding to develop a blood clotting enzyme and Factor XIII product. Drug Manufacturer Compliance Programs are beginning to oversee vendors' compliance policies, companies tell Food and Drug Law Institute conference. Glaxo recommends contracts require vendors to have compliance programs.
Firms say they are preparing to conduct compliance audits of vendors.
Inc. publications are protected by U.S. Copyright Law. Reproduction, photocopying, storage or re-transmission by magnetic or electronic means is strictly prohibited by law. You may download these pages for your personal use only.